Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALI-2108 in Fibrostenotic Crohn's Disease
NCT07428096Phase 1Active, not recruiting
- Sponsor
- Palisade Bio
- Start
- Oct 2025
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of PALI-2108 in Crohn's disease, sponsored by Palisade Bio. Primary endpoint: Safety and tolerability of PALI-2108 at 14 days. Started Oct 2025; status: active, not recruiting.
02
Drugs
PALI-2108
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07428096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07428096.